Summer Sessions 4: Dr. Loretta Itri On Taking ADCs Across The Finish Line

We love to hear from our listeners. Send us a message. While Immunomedics CMO Loretta Itri, M.D. is no stranger to taking drugs across the commercial finish line in big pharma, her most recent win with TRODELVY was very, very different. Here, Dr. Itri shares insight on her small biopharma's first commercial launch, the manufacturing and regulatory challenges overcome to get there, and why ADCs are coming of age.Access this and hundreds of episodes of the Business of Biotech videocast under th...